Free Trial
→ Why Gerardo Del Real says wait before buying uranium stocks (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$2.52
-2.3%		$3.18
$2.49
▼
$14.91
$32.37M6.9761,795 shs102,452 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$7.90
-9.4%		$10.84
$3.23
▼
$315.00
$8.96M245,218 shs31,716 shs
RYTHM, Inc. stock logo
RYM
RYTHM
$16.16
-5.2%		$20.65
$14.00
▼
$50.38
$37.13M9.4618,699 shs1,211 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+505.97%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-2.33%-4.55%-22.22%-14.29%-75.48%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-9.40%+21.54%-21.06%-1.25%-96.71%
RYTHM, Inc. stock logo
RYM
RYTHM
-5.16%+3.00%-22.94%-10.82%-61.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$2.52
-2.3%		$3.18
$2.49
▼
$14.91
$32.37M6.9761,795 shs102,452 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$7.90
-9.4%		$10.84
$3.23
▼
$315.00
$8.96M245,218 shs31,716 shs
RYTHM, Inc. stock logo
RYM
RYTHM
$16.16
-5.2%		$20.65
$14.00
▼
$50.38
$37.13M9.4618,699 shs1,211 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+505.97%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-2.33%-4.55%-22.22%-14.29%-75.48%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-9.40%+21.54%-21.06%-1.25%-96.71%
RYTHM, Inc. stock logo
RYM
RYTHM
-5.16%+3.00%-22.94%-10.82%-61.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
1.67
Reduce$18.00614.29% Upside
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.33
Hold$60.00659.49% Upside
RYTHM, Inc. stock logo
RYM
RYTHM
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest MBRX, RYM, ADXS, and IXHL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/6/2026
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
8/28/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$60.00
8/13/2026
RYTHM, Inc. stock logo
RYM
RYTHM
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M11.05N/AN/A($2.06) per share-0.29
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/A$5.63 per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$93.81 per shareN/A
RYTHM, Inc. stock logo
RYM
RYTHM
$51.01M0.69N/AN/A$6.06 per share2.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$19.30M-$1.69N/AN/AN/AN/A-25.62%-24.46%11/13/2026 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$33.56M-$7.13N/AN/AN/AN/A-143.51%-24.53%11/12/2026 (Estimated)
RYTHM, Inc. stock logo
RYM
RYTHM
-$33.26M-$10.53N/AN/AN/A-6.20%-12.57%-2.60%N/A

Latest MBRX, RYM, ADXS, and IXHL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q1 2027
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$0.66N/AN/AN/A$10.00 millionN/A
11/12/2026Q3 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$8.8667N/AN/AN/AN/AN/A
9/26/2026Q4 2026
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$0.13-$0.14-$0.27-$0.2030$0.20 millionN/A
8/13/2026Q2 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$31.00-$28.00+$3.00-$1.40N/AN/A
8/4/2026Q2 2026
RYTHM, Inc. stock logo
RYM
RYTHM
N/A$0.09N/A$0.09N/A$23.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/A
48.81
48.81
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
0.94
0.94
RYTHM, Inc. stock logo
RYM
RYTHM
N/A
0.59
0.56

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
0.43%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
RYTHM, Inc. stock logo
RYM
RYTHM
5.98%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
1.33%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
18.04%
RYTHM, Inc. stock logo
RYM
RYTHM
3.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2059.31 million42.36 millionNot Optionable
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
1212.55 million12.38 millionOptionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
171.03 million842,000Not Optionable
RYTHM, Inc. stock logo
RYM
RYTHM
1412.18 million2.10 millionN/A

Recent News About These Companies

Can RYTHM (NASDAQ:RYM) Lean on Brand Licensing as Hemp Rules Tighten?
October 28 at 11:57 PM  |  kalkinemedia.comK
RYTHM (NASDAQ:RYM) and Trulieve Cannabis (NYSE:TRLV) Head to Head Review
October 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31154200
RYTHM Introduces Lifted Lemon, a New THC Twist on Iced Tea and Lemonade
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348222/0/en/rythm-introduces-lifted-lemon-a-new-thc-twist-on-iced-tea-and-lemonade.html
RYTHM Inc
August 19, 2026  |  markets.ft.comhttps://markets.ft.com/data/equities/tearsheet/summary?s=RYM:NAQ
RYTHM Shareholders Approve Dilutive Equity Issuance Changes
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rythm-shareholders-approve-dilutive-equity-issuance-changes?utm_source=marketbeat.com&utm_medium=referral
RYTHM Swings to Earnings in Q2 on THC Beverage Growth
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971401/rythm-swings-to-earnings-in-q2-on-thc-beverage-growth?cid=cs-stocknewsapi-ft-microcap_article|earnings-2971401
RYTHM, Inc. Reports Record Second-Quarter 2026 Revenue Growth and Strong THC Beverage Momentum
August 4, 2026  |  quiverquant.comQ
RYTHM, Inc. Reports Second Quarter 2026 Results
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338135/0/en/rythm-inc-reports-second-quarter-2026-results.html
RYTHM (NASDAQ:RYM) Trading Up 14% – Time to Buy?
August 4, 2026  |  defenseworld.netD
RYTHM, Inc. (RYM) Stock Major Holders - Yahoo Finance
July 27, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/RYM/holders/
Señorita Brings THC Beverages to Lollapalooza for the First Time
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332009/0/en/se%c3%b1orita-brings-thc-beverages-to-lollapalooza-for-the-first-time.html
Rythm Stock Short Interest Report | NASDAQ:RYM | Benzinga
July 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/RYM/short-interest
RYTHM (NASDAQ:RYM) Director Sells 2,250 Shares
June 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rym-insider-buying-and-selling-2026-06-19/
RYTHM Inc.
May 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/rym/financials/cash-flow
Señorita Named Official THC Beverage Partner of Opry Entertainment Group Venues
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294752/0/en/se%c3%b1orita-named-official-thc-beverage-partner-of-opry-entertainment-group-venues.html
Rythm Inc Ordinary Shares RYM
May 13, 2026  |  morningstar.comM
RYTHM Stock Price History
May 12, 2026  |  investing.comhttps://www.investing.com/equities/agrify-corp-historical-data
RYTHM's Q1 Earnings Rise Y/Y on Licensing Agreement Benefits
May 11, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2919257/rythm-s-q1-earnings-rise-y-y-on-licensing-agreement-benefits?cid=cs-stocknewsapi-ft-microcap_article|earnings-2919257
Navy Pier Names RYTHM as Its Official THC Beverage Partner
May 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291219/0/en/navy-pier-names-rythm-as-its-official-thc-beverage-partner.html
RYTHM, Inc. Reports First Quarter 2026 Results
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288216/0/en/rythm-inc-reports-first-quarter-2026-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)
As of 10/30/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Incannex Healthcare stock logo

Incannex Healthcare NASDAQ:IXHL

$2.52 -0.06 (-2.33%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$2.56 +0.04 (+1.59%)
As of 10/30/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$7.90 -0.82 (-9.40%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$8.02 +0.12 (+1.52%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

RYTHM stock logo

RYTHM NASDAQ:RYM

$16.16 -0.88 (-5.16%)
Closing price 10/30/2026 03:58 PM Eastern
Extended Trading
$16.16 0.00 (-0.03%)
As of 10/30/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas